Cargando…
Anticancer Impact of Nitric Oxide (NO) and NO Combination with SMYD-3 Inhibitor on Breast Carcinomas
Despite enormous advances in the detection and treatment of breast cancer, it still remains the leading cancer diagnosis and has the second highest mortality rate. Thus, breast cancer research is a high priority for academics and clinicians alike. Based on previous research indicating the potential...
Autores principales: | Gordon, Jenna L., Hinsen, Kristin J., Reynolds, Melissa M., Brown, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628812/ https://www.ncbi.nlm.nih.gov/pubmed/34842655 http://dx.doi.org/10.3390/diseases9040082 |
Ejemplares similares
-
Anticancer potential of nitric oxide (NO) in neuroblastoma treatment
por: Gordon, Jenna L., et al.
Publicado: (2021) -
Nitric Oxide as a Potential Adjuvant Therapeutic for Neuroblastoma: Effects of NO on Murine N2a Cells
por: Gordon, Jenna L., et al.
Publicado: (2020) -
In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells
por: Alshiraihi, Ilham M., et al.
Publicado: (2020) -
Nitric oxide-releasing emulsion with hyaluronic acid and vitamin E
por: Yapor, Janet P., et al.
Publicado: (2019) -
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma
por: Binh, Mai Thanh, et al.
Publicado: (2020)